|Bid||31.670 x 900|
|Ask||31.750 x 1400|
|Day's Range||28.080 - 31.860|
|52 Week Range||15.200 - 40.750|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a). Additional data from the Phase 2 study will be presented as a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018. The goal of the Phase 2 study was to characterize the safety and tolerability of AKCEA-APO(a)-LRx and to inform dose and dose frequency selection for the planned Phase 3 cardiovascular outcomes study. The randomized, double-blind, placebo-controlled, dose-ranging study included 286 patients with established CVD and high Lp(a) (baseline mean of approximately 100 mg/dL [250 nmol/L] – more than three times the upper limit of normal).
Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood. The company said it expected to book charges of $2 million to $2.5 million in the third quarter https://www.sec.gov/Archives/edgar/data/1662524/000114036118037945/form8k.htm, as a result of the decision, which affects only U.S. employees involved in functions focused on Waylivra.
Cambridge-based Akcea Therapeutics Inc. said Thursday that it plans to lay off 10 percent of its workforce following the FDA's rejection of its rare disease drug last week. While Akcea (Nasdaq: AKCA) did not say how many people would be laid off, the company told the Business Journal in June that it had more than 200 employees. In a statement, Akcea said the company remains "very disappointed" with the FDA's decision not to approve its drug, called Waylivra, which targets a lipid disorder called familial chylomicronemia syndrome, or FCS.
Akcea Therapeutics, Inc.(AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company overview at the Wells Fargo Healthcare Conference at 4:10 p.m. ET on Wednesday, September 5, 2018 in Boston. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases.
Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. got a rude surprise last night after the Food and Drug Administration issued a complete response letter on their Waylivra, following a contentious vote at a May advisory committee meeting. Peer Alnylam Pharmaceuticals Inc. shares soared yesterday on Pfizer Inc.’s results for a competing treatment for the same disease, ATTR, but in the cardiomyopathy type. Many analysts covering Ionis and Akcea remain optimistic ahead of a FDA decision on Tegsedi, expected by Oct. 6.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Toyota Motor Corp (ADR) (NYSE: TM ) stock was trading ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting 52-week highs on Aug. 27) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
Waylivra is one of two drugs Akcea was planning to launch in the next year or two, according to Akcea President Sarah Boyce.
Akcea Therapeutics, Inc. (AKCA) an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that they received a Complete Response Letter (CRL) from the Division of Metabolism and Endocrinology Products of the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for WAYLIVRA™(volanesorsen). “We are extremely disappointed with the FDA’s decision. Familial chylomicronemia syndrome (FCS) is an ultra-rare, devastating hereditary disease that causes unpredictable and potentially fatal acute pancreatitis, chronic complications due to permanent organ damage, and a severe impact on daily living.
Multiple pharma stocks are making sympathy moves Monday in reaction to data released at the 2018 European Society of Cardiology Congress in Munich, Germany. Pfizer Inc. (NYSE: PFE ) shares are trading ...
Pfizer Inc. (PFE) shares rose just under 1% in Monday premarket trade after the company announced positive results from a late-stage trial of its drug tafamidis, which is being developed for the rare disease transthyretin amyloid cardiomyopathy. The Pfizer results were strong but "we see the door open to ALNY given key details of the study: 1) 20 mg not differentiated from 80 mg, and 2) more limited efficacy in the ATTRm population (vs wild-type) and would not be surprised to see ALNY shares trade up," said EvercoreISI analyst Josh Schimmer and Steven Breazzano, who went on to say that two rival therapies, Alnylam Pharmaceuticals Inc.'s (ALNY) patisiran and Ionis Pharmaceuticals Inc. (IONS) and Akcea Therapeutics Inc.'s (AKCA) inotersen, "will generally be safe in the neuropathy population." Alnylam shares rose 4.3% in premarket trade while Ionis and Akcea shares were inactive.
Investors need to pay close attention to Akcea Therapeutics (AKCA) stock based on the movements in the options market lately.
Alnylam is one of several local biotechs developing drugs based on Nobel Prize-winning technology known as RNA interference.
It's hard to make a profit that way, but the situation seems temporary as the biotech waits for FDA approval of two drugs.
Investors betting on Tesla’s stock stumbling took a beating this week when shares in the company rallied after CEO Elon Musk tweeted that he was considering taking the company private.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on Aug. 7) Akcea Therapeutics Inc (NASDAQ: AKCA )(reacted to Q2 earnings ...
TEGSEDI™ Approved in European Union $382 million to fund the company through key milestones in 2019. Conference Call Webcast Monday, August 6, 4:30 p.m. ET at www.akceatx.com. CAMBRIDGE, Mass., Aug. 06, ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Akcea Therapeutics, Inc. (NASDAQ: AKCA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...
TEGSEDI has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). TEGSEDI is also the subject of a pending new drug application in the U.S. and Canada.